Your browser doesn't support javascript.
loading
Structural and Physicochemical Features of Oral PROTACs.
Schade, Markus; Scott, James S; Hayhow, Thomas G; Pike, Andy; Terstiege, Ina; Ahlqvist, Marie; Johansson, Johan R; Diene, Coura R; Fallan, Charlene; Balazs, Amber Y S; Chiarparin, Elisabetta; Wilson, David.
Afiliação
  • Schade M; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Scott JS; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Hayhow TG; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Pike A; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Terstiege I; Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
  • Ahlqvist M; Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
  • Johansson JR; Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
  • Diene CR; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Fallan C; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Balazs AYS; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
  • Chiarparin E; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Wilson D; Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
J Med Chem ; 67(15): 13106-13116, 2024 Aug 08.
Article em En | MEDLINE | ID: mdl-39078401
ABSTRACT
Achieving oral bioavailability with Proteolysis Targeting Chimeras (PROTACs) is a key challenge. Here, we report the in vivo pharmacokinetic properties in mouse, rat, and dog of four clinical oral PROTACs and compare with an internally derived data set. We use NMR to determine 3D molecular conformations and structural preorganization free in solution, and we introduce the new experimental descriptors, solvent-exposed H-bond donors (eHBD), and acceptors (eHBA). We derive an upper limit of eHBD ≤ 2 for oral PROTACs in apolar environments and show a greater tolerance for other properties (eHBA, polarity, lipophilicity, and molecular weight) than for Rule-of-5 compliant oral drugs. Within a set of structurally related PROTACs, we show that examples with eHBD > 2 have much lower oral bioavailability than those that have eHBD ≤ 2. We summarize our findings as an experimental "Rule-of-oral-PROTACs" in order to assist medicinal chemists to achieve oral bioavailability in this challenging space.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article